The primary aim of this systematic review was to assess the effect on neonatal outcome of pharmacological interventions used for attenuation of the haemodynamic response to tracheal intubation in patients undergoing caesarean section under general anaesthesia. A systematic search of randomised controlled trials from 1990 to 2015 was conducted. The primary outcome measure was the Apgar score at five minutes and secondary outcomes were umbilical arterial blood gas parameters and neurological adaptive capacity scores. Twenty-seven randomised controlled trials (1,689 patients) were included in the qualitative synthesis. Only five studies using opioids (383 patients) and five studies using non-opioid analgesics (358 patients) were subjected to meta-analysis. The Apgar score at five minutes was significantly lower in neonates of opioid-treated mothers (mean difference: -0.29, 95% confidence interval -0.56 to -0.02, P-value=0.03) compared to mothers in the control group; the umbilical arterial pH was lower and there was a higher requirement for tactile stimulation in neonates. No difference was seen in Apgar scores of neonates of mothers administered non-opioid analgesics compared to placebo. No difference was observed in other parameters between opioid-or non-opioid-treated mothers. This review suggests that opioid interventions for attenuation of the haemodynamic response to tracheal intubation in pregnant patients under general anaesthesia affect neonatal Apgar scores at five minutes in neonates but the difference did not appear to be clinically meaningful. We were unable to demonstrate any difference in safety.
1
. Although the majority of caesarean deliveries are performed under neuraxial anaesthesia, general anaesthesia is still required for some maternal and fetal indications. Laryngoscopy and tracheal intubation with rapid sequence induction is often accompanied by circulatory and hormonal responses which may be detrimental in patients with cardiac disease and pregnancy-induced hypertension 2 . Several drugs have been used to attenuate these responses in patients undergoing caesarean section, including remifentanil 3 , labetalol 4 , and magnesium 5 . There is insufficient evidence to support one drug as first-line therapy especially in pre-eclamptic women. Ideally, these drugs should be quickly cleared and have minimal placental transfer with no significant fetal or neonatal effects 6 . The primary objective of this systematic review was to evaluate neonatal outcomes following pharmacological intervention for attenuation of the maternal haemodynamic response to tracheal intubation during caesarean section under general anaesthesia.
Methods

Study selection criteria
Inclusion criteria
Criteria for including studies in this systematic review were as follows:
Types of studies: Prospective randomised controlled trials conducted where the primary objective was to study the effect of different pharmacological agents on the haemodynamic response to laryngoscopy and tracheal intubation in patients undergoing caesarean section under general anaesthesia were included. We included trials which had placebo or other drugs as a control group. We included both blinded and unblinded trials.
Type of participants: Women undergoing either elective or emergency caesarean section under general anaesthesia were included.
Type of intervention: We included trials where pharmacological agents were given for the specific purpose of attenuating the tracheal intubation-associated haemodynamic response in pregnant patients.
Outcome measures: We included randomised controlled trials which reported the following primary or secondary neonatal outcomes in the methodology or results: a primary outcome measure of Apgar score at five minutes, secondary outcome measures of neonatal umbilical arterial and venous blood gas parameters, Neurologic and Adaptive Capacity Scores (NACS), hypothermia, bradycardia, respiratory depression and maternal hypotension.
Exclusion criteria
We excluded articles where the effect of routinely used drugs, for example induction agents, inhalational anaesthetics and muscle relaxants, on the haemodynamic response to tracheal intubation were studied.
Literature search
The databases Medical Literature Analysis and Retrieval System Online, Cumulative Index of Nursing and Allied Health Literature and Cochrane Central Register of Controlled Trials were systematically searched for articles published between 1 January 1990 to 31 December 2015 (26 years). The following keywords were used: 'obstetrics patient', 'parturient', 'pregnancy', 'pregnant females', 'caesarean section', 'caesarean deliveries', 'general anaesthesia for caesarean section', 'rapid sequence induction', 'pregnancy induced hypertension', 'gestational hypertension', 'gestational hypertensive disease', 'pre-eclampsia', 'preeclamptics', 'laryngoscopic response', 'tracheal response', 'intubation response', 'haemodynamic response', 'stress response', 'hormonal response', 'peri-induction hypertension', 'cardiovascular effects', 'complications', 'pharmacological agents', 'beta-blockers', 'beta adrenergic antagonist', 'b-blocking drugs', 'esmolol', 'labetalol', 'local anaesthetics', 'lignocaine', 'opioids', 'fentanyl', 'alfentanil', 'sufentanil', 'remifentanil', 'calcium channel blockers', 'calcium channel antagonists', 'nifedipine', 'nicardipine', 'direct vasodilators', 'nitroglycerin', 'nitroprusside', 'hydralazine', 'magnesium sulphate', 'neonatal outcomes', 'Apgar scores', 'neonatal pH', 'umbilical cord pH', 'umbilical artery pH', 'umbilical venous pH', 'neuroadaptive and capacity scores'.
We searched Google Scholar for any additional references. The reference lists of included papers were also scrutinised for additional articles. We used Google Translate for trials that were not written in English. We did not seek unpublished studies.
Data extraction, handling and analysis
Two authors independently reviewed the titles and the abstracts of the studies and reached a consensus on the abstracts that met the inclusion criteria. In case of any disagreement, a third identified reviewer was consulted.
The full text of all included studies was obtained. Two authors then independently reviewed the full texts. Any disagreements were discussed with a third reviewer. The names of the authors, the institution, or the journal of publication were not blinded. The information extracted was recorded on a specially designed form.
Assessment of risk of bias in included studies
We independently evaluated the validity and design characteristics of each selected study. This included random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data and selective reporting as recommended in the Cochrane Collaboration's recommended tool for assessing risk of bias 7 . 
Measurement of effect
The primary outcome measure was the Apgar score at five minutes. In some studies 8, 9, 10 , authors reported the median and range of the Apgar scores for which we computed the mean and standard deviation (SD) by using the calculator available on http://www.iun.edu/~mathiho/ medmath/Estimating.xls 11 . We estimated the combined different reported subgroups into a single group according to the combined group formula described in the Cochrane Manual 12 . The mean difference (MD) was calculated as the effect size for measurement data. For dichotomous data, the risk difference with a 95% confidence interval (CI) was calculated. Forest plots were constructed and statistical significance was considered if the pooled 95% CI excluded zero difference. Chi-square test and I 2 were performed to assess heterogeneity between studies. We adhered to the PRISMA checklist for reporting meta-analyses. All metaanalyses were performed using Review Manager, version 5 software (The Cochrane Collaboration, Oxford, UK), with a random effect model.
Results
The flow chart for the literature search and study selection is shown in Figure 1 . Our initial literature search identified 178 abstracts through the database search and 18 abstracts through a manual search, of which 27 studies were considered eligible for qualitative synthesis. These studies included 1,689 patients with an average age of 29 years (SD 2.7, range 22 to 34 years). Information regarding anaesthetic agents used and maternal factors is given in Table 1 .
Eighteen studies used a saline placebo control group, ten compared opioid drugs with a placebo control and eight compared non-opioid interventions. Ten were included in the meta-analysis, five from the opioid group and five from the non-opioid group.
Nine studies without placebo-controlled groups either compared one study drug with another or different dosages of the same drug. These nine studies without placebocontrolled trials were included in the qualitative synthesis but were not analysed quantitatively.
Opioid drug intervention versus placebo-controlled studies
Ten studies compared opioids with placebo 3, [13] [14] [15] [16] [17] [18] [19] [20] [21] . The sample size varied from 40 to 151 participants. Six studies investigated remifentanil 3, [15] [16] [17] 20, 21 , two studies alfentanil 13, 18 , one study fentanyl 14 , and one study nalbuphine 19 . An intravenous (IV) opioid bolus was used in nine studies 3, [13] [14] [15] [16] [17] [18] [19] 21 and a bolus followed by an infusion in the remaining study 20 . In nine studies, the patients investigated underwent elective caesarean section [13] [14] [15] [16] [17] [18] [19] [20] [21] . One study, Yoo et al, recruited patients undergoing both elective and emergency caesarean section 3 . Seven studies included only term parturients [13] [14] [15] [16] [17] 19, 20 , one preterm parturients 21 and the type of parturients was not mentioned in two studies 3, 18 . In seven studies [13] [14] [15] [16] [17] 19, 20 pre-eclamptic patients were excluded. One study admitted pre-eclamptic patients 3 and two did not mention the details regarding presence of pre-eclampsia 18, 21 . Apgar score at five minutes All studies using opioids reported Apgar scores at five minutes, however, in three studies Apgar scores were given as categorical data and these were excluded from metaanalysis 13, 15, 16 . The study which investigated nalbuphine 19 was also excluded from the meta-analysis because nalbuphine is a synthetic opioid agonist-antagonist and has different pharmacokinetics from the rest of the opioids. The study by Yoo et al included both elective and emergency caesarean sections and was also excluded from meta-analysis 3 .
The number of patients included in the remaining five studies 14, 17, 18, 20, 21 in the meta-analysis was 192 in the opioid and 191 in the placebo group. Mean Apgar score at five minutes was statistically significantly lower (mean difference -0.29, 95% CI -0.56 to -0.02, P=0.03, I 2 =80%) in the opioidtreated mothers compared to those receiving placebo medication ( Figure 2 ).
Comparison of other parameters
Umbilical arterial blood pH difference was statistically significant between the opioid-treated mother group compared with the control group [standardised mean difference (SMD) 0.23, 95% CI 0.01 to 0.45, P=0.04, I
2 =0%], the pH being lower in the opioid-treated mother group. This was reported in seven studies 3, [13] [14] [15] [16] [17] 20 . No difference was observed for partial pressure of oxygen, carbon dioxide (PaCO 2 ), and base excess in umbilical arterial and venous blood between the opioid-treated groups and the control groups.
Two studies 3, 20 in the opioid group (n=84) reported tracheal intubation in neonates. Eight neonates in the opioid group required tracheal intubation compared to four in the placebo group but this difference was not significant (odds ratio Time to sustained respiration was reported in two studies 15, 19 but as one of the studies investigated nalbuphine 19 , it was not analysed. Hypothermia and bradycardia in neonates was not reported in any study. NACS scores were reported in one study with opioid 13 . NACS scores at 15 and 120 minutes were similar between the groups. Neonatal peripheral oxygen saturation (SpO 2 ) was reported in one study 18 in an opioid group and it was not significantly different between the groups.
Non-opioid drug intervention versus placebo-controlled studies
Eight studies 8-10,22-26 compared non-opioid pharmacological interventions (n=211) with placebo controls (n=177). The sample size varied from 30 to 90 in different studies. Two studies investigated paracetamol 23, 24 , one study lidocaine 8 , one study ketorolac 9 , one study tenoxicam 10 , one study nifedipine 22 , one study landiolol 25 and one study dexmedetomidine 26 . An IV bolus was used in five studies 9, 10, [23] [24] [25] , IV infusion in one 26 and a combination of IV bolus and infusion in one 8 . The oral route was used in one study 22 .
In six studies [8] [9] [10] 23, 25, 26 , the patients investigated underwent elective caesarean section, one study recruited patients undergoing urgent caesarean section 24 and one did not mention the nature of caesarean section 22 . Three studies included only term parturients 8, 9, 26 , five studies did not mention the term status 10, [22] [23] [24] [25] . As regards type of patients, in seven studies [8] [9] [10] [23] [24] [25] [26] , pre-eclamptic patients were excluded and only one study included patients with pregnancy-induced hypertension 22 . Apgar score at five minutes All eight studies reported the Apgar score at five minutes, however, in one study the Apgar score was given as categorical data and in another study, Apgar scores data was not provided but it was mentioned that there was no difference in the scores. These last two studies were excluded from meta-analysis 24, 25 . Kumar et al did not give the status of patients with regard to elective or emergency caesarean section, hence this study was also excluded from meta-analysis 22 . The number of patients in the five included studies [8] [9] [10] 23, 26 was 196 in the non-opioid group and 162 in the placebo group. There was no difference in the mean five minute Apgar score between non-opioid and placebo groups (mean difference 0.12, 95% CI -0.11 to 0.34, P=0.31, I 2 =74%) ( Figure 3 ).
Comparison of other parameters
Secondary outcomes are shown in Table 3 . No difference was found between the non-opioid and placebo groups for any secondary outcome measures.
Studies without a placebo control group
Nine studies 5, [27] [28] [29] [30] [31] [32] [33] [34] were without a placebo control group. The sample size varied from 38 to 120 participants. Two studies 30, 33 investigated different dosages of a single drug (remifentanil), five studies 5,29,31,32,34 compared two drugs of either the same (remifentanil versus fentanyl, fentanyl versus alfentanil) or different pharmacological groups (remifentanil versus dexmedetomidine, esmolol versus lidocaine, magnesium sulphate versus alfentanil) and two studies 27, 28 investigated three drugs (lidocaine versus magnesium sulphate versus alfentanil, nifedipine versus nitroglycerin versus hydralazine). These studies were not included in the meta-analysis. Neonatal outcomes observed in these studies are presented in Table 5 .
An IV bolus was used in six studies 5, 28, [30] [31] [32] [33] [34] , an IV infusion was used in three studies 27, 29, 31 and the oral route in one study 27 . In eight studies 5, 27, 28, [30] [31] [32] [33] [34] , only pre-eclamptic patients were included. One study 29 excluded patients with pregnancy-induced hypertension and pre-eclampsia. Six studies 5, 27, 28, 30, 33, 34 included patients undergoing elective or emergency caesarean section, one study 29 recruited patients undergoing elective caesarean section only, while one study 32 included emergency caesarean section only. One study 31 did not mention the elective or emergency status. Six studies 5, 28, 30, [32] [33] [34] included preterm parturients, two studies 27, 29 included only term parturients and one study 31 did not mention the term status. Table 6 shows the efficacy and maternal haemodynamic effects of pharmacological agents used for attenuation of the haemodynamic response to tracheal intubation in the studies included in the meta-analysis. The effect of short-acting opioids on the haemodynamic response of parturients was dose-dependent, with lower doses of remifentanil having an equivocal effect. A higher dose of 1 µg/kg of remifentanil was effective in blunting the blood pressure and heart rate response to intubation 21 . Remifentanil 17 0.5 µg/kg and alfentanil 18 10 µg/kg did not affect the heart rate but attenuated the blood pressure response. Fentanyl 14 in a dose of 1 µg/kg was effective in attenuating the response.
Efficacy and maternal haemodynamic effects of pharmacological agents
In the non-opioid group, paracetamol 23 , ketorolac 9 , lidocaine 8 , and dexmedetomidine 26 were all effective in lowering systolic blood pressure, mean blood pressure and heart rate when compared with placebo.
We looked for maternal hypotension and bradycardia in the included studies. Maternal bradycardia or hypotension was not reported in any study.
Quality of included studies
The quality of each study was assessed on the basis of presence and absence of the risk of bias. This information is given in Table 7 . In 49% of the studies, the details of randomisation and allocation concealment were mentioned. One study had a high risk of randomisation bias and one study had a high risk of allocation bias. Blinding of participants occurred in 62% of studies. Blinding of outcome assessors occurred in 74% of studies. Fifty-five percent of the studies showed low risk of incomplete outcome data bias while 77% had a low risk of selective outcome reporting.
Discussion
This review found that five minute Apgar scores of neonates born to mothers who received an opioid-based intervention for attenuation of the haemodynamic response to tracheal intubation were lower compared to those whose mothers received a placebo. Though the difference was statistically significant, from a clinical perspective it did not appear to be important as the Apgar score in both groups remained above seven. The requirement for tactile stimulation was higher and the umbilical arterial pH was lower in the neonates whose mothers received opioids. In contrast, no statistical difference was observed in the five minute Apgar score and other parameters in neonates whose mothers were treated with non-opioid interventions for blunting intubation response in comparison to placebo.
Several pharmacological agents have been used in the nonobstetric population to effectively blunt the haemodynamic response to tracheal intubation. A Cochrane review on prevention of morbidity associated with the haemodynamic response to tracheal intubation listed local anaesthetics, beta-blockers, calcium channel blockers and opioids as effective therapy in blunting the response and reducing the incidence of arrhythmias associated with intubation 35 . In the obstetric setting, this rise in blood pressure and heart rate can be detrimental in a subset of patients with preeclampsia and needs to be prevented 6 . In this particular group of patients the ideal drug should attenuate this response in the parturient with minimal side-effects for both mother and baby. Opioids like remifentanil 20, 21 , fentanyl 14 23 , and esmolol 34 have also been effectively used.
A systematic review of the effect of remifentanil on the maternal stress response and neonates has previously been conducted by Heesan et al 36 . Their analysis found a higher base excess and higher pH in neonates of remifentaniltreated mothers. However, they did not observe a difference in Apgar scores (n=61), need for intubation (n=71), or mask ventilation (n=72) in infants where mothers were treated with remifentanil compared to control. A small number of patients was the most likely reason for the lack of differences between remifentanil-treated mothers and the control group 36 . Some studies have looked at neonatal effects of drugs used for attenuating the haemodynamic response of mothers. A lower Apgar score at one minute was observed by Yoo et al 3 with remifentanil 1 µg/kg as well as a greater need for resuscitative measures in neonates (P=0.04), however the Apgar score was similar in both groups at five minutes. This result was different from a study by Ngan Kee et al 15 who Figure 3 : Comparison of mean Apgar score at five minutes, non-opioid group versus control group. IV, inverse variance; Random, random effect model; SD, standard deviation; CI, confidence interval.
used the same dose but found no difference between the groups. This difference could be due to the fact that Ngan Kee et al conducted their study in term parturients without pre-eclampsia whereas Yoo et al included pre-eclamptic patients with preterm neonates who may be more sensitive to opioids given to mothers. Heterogeneity of neonatal effects in individual studies can also be explained on the basis that placental permeability and pharmacokinetic properties determine the fetal exposure to maternal drugs. Several factors affect drug transfer across the placenta, e.g. lipid solubility, protein binding, tissue binding, pKa, and pH 37 . Alteration in placental blood flow can occur due to maternal hypotension or inadvertent hyperventilation during anaesthesia which may lead to a fall in PaCO 2 and to neonatal effects. Not all these factors can be controlled in clinical studies. Maternal bradycardia or hypotension was not reported in any of the studies included in meta-analysis.
Other factors that can affect fetal exposure to maternally administered drugs are the time between induction of anaesthesia and clamping of the umbilical cord, and uterine incision to delivery time. A prolonged uterine incision to delivery time is associated with an increase in the incidence of fetal acidosis, presumably due to uteroplacental vasoconstriction 38 . Not all included studies reported these parameters. Differences in induction agents and variation in their dose in different studies may also have an impact on neonatal outcome.
Another aspect that merits discussion in reference to this review is the use of tools for assessment of neonatal effects. The Apgar score is widely used to assess neonates although its value has been questioned 39 . Its limitations include that it can be low due to a variety of reasons apart from drug exposure. These reasons could be preterm delivery, congenital abnormality, neuromuscular disease and IV bolus Apgar scores at 1 and 5 min, umbilical cord arterial and venous blood gas analysis and number of neonates who required resuscitative measures (tactile stimulation, bag-mask ventilation, tracheal intubation) and admission to NICU Elec, elective; Em, emergency; IV, intravenous; NTG, nitroglycerin; NICU, neonatal intensive care unit; N, total number of participants in study; (n), number of participants in treatment and control groups; MgSO4, magnesium sulphate; min, minutes; NACS, Neurologic and Adaptive Capacity Score. instrumental delivery. Traditionally the Apgar score at both one and five minutes has been reported. The five minute Apgar score is now considered a more useful clinical index for predicting resuscitation as well as the increased risk of adverse neurological outcome in comparison to the one minute score. The American Academy of Pediatrics defines a five minute Apgar score between seven to ten as reassuring as far as fetal outcome is concerned 40 . A large Swedish study found an association between a transiently low Apgar score without encephalopathy and poor performance in cognitive testing done at age 18 years. However the authors state that this association is modest and unlikely to be of clinical significance 41 . NACS has also been used to document the effects of analgesic and anaesthetic agents and techniques on neonatal neurobehaviour. A systematic review regarding use of NACS in obstetric anaesthesia research concluded that reliability and validity of this evaluation tool was lacking 42 . Umbilical arterial blood pH, base excess and PaCO 2 measurements reflect fetal and immediate neonatal condition whereas umbilical venous blood values reflect maternal acid-base status and placental function 43 . These measurements may be a more objective indicator than the Apgar score, but were not recorded in all included studies. In our analysis, a small but statistically significant difference was observed in umbilical arterial blood pH between the opioid and non-opioid groups, with lower values in the opioid group. This decrease probably reflects a small reduction in oxygen delivery to the fetus and could be due to a number of reasons. Maternal hypotension or hypovolaemia was only documented in two studies 3, 16 in the review but both these studies were excluded from meta-analysis. There is a possibility that maternal hypotension could have occurred in some patients in other included studies where these parameters were not recorded.
Nine studies with no placebo group and which compared varying doses of different pharmacological agents were not included in our standard pair-wise meta-analysis. In such situations a multi-treatment comparison meta-analysis or a network meta-analysis which simultaneously analyses both direct and indirect comparisons of interventions within a randomised controlled trial is a better option to compare the effectiveness of drugs. This technique, though more robust in such situations, is still associated with methodological challenges 44 . We were unable to conduct this due to unavailability of expertise in this area.
Limitations of this review
A limitation of this review is that our primary outcome of the five minute Apgar score was not the primary but a secondary outcome in the included studies. Studies reported Apgar scores differently and defined different categories of Apgar scores as per their convenience; therefore, the quality aspect in future research in a standardised manner. In clinical practice, the use of agents to reduce the response to laryngoscopy and intubation is likely to be of most importance in those patients at high risk of morbidity due to hypertensive disorders or concurrent cardiovascular disease and these patients are also at high risk for premature caesarean delivery. This review therefore highlights the need to study this particular group separately.
Conclusion
This review suggests that short-acting opioid interventions for attenuation of the circulatory response to tracheal intubation in pregnant patients undergoing elective caesarean section with general anaesthesia is associated with a small decrease in five minute Apgar scores and umbilical artery pH but the difference did not appear to be clinically meaningful. We did not find any effects of nonopioid pharmacological interventions on neonatal outcomes. In conclusion, both techniques are safe to use and should not be chosen based upon neonatal effects. The available evidence does not allow us to recommend a specific drug, dose or route of administration for these agents.
